Focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure
Founded in 2021, Corteria Pharmaceuticals is a privately held company developing first-in-class drugs in heart failure subpopulations. Our strategy implies innovative patient stratification and target selection based on human evidence and a better understanding of the disease biology in patients.
We are using cutting-edge methods to stratify the patients and identify those who will benefit the most from our treatments. Our focus is on worsening and acute heart failure.